دورية أكاديمية
4CMenB Vaccination to Prevent Meningococcal B Disease in Vietnam: Expert Review and Opinion.
| العنوان: | 4CMenB Vaccination to Prevent Meningococcal B Disease in Vietnam: Expert Review and Opinion. |
|---|---|
| المؤلفون: | Nguyen PNT; Pediatrics Department, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam., Thai PQ; Communicable Diseases Control and Prevention Department, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam., Dien TM; National Pediatric Hospital, Hanoi, Vietnam., Hai DT; Center for Tropical Diseases, National Pediatric Hospital, Hanoi, Vietnam., Dai VTT; Respiratory Microbiology Bacteria Laboratory, Department of Immunology and Microbiology, the Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City, Vietnam., Luan NH; Immunization Unit of University of Medicine and Pharmacy Hospital, Pediatrics Department, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam., Mathur G; GSK, Ho Chi Minh City, Vietnam., Badur S; GSK, Istanbul, Turkey., Truyen DM; GSK, Ho Chi Minh City, Vietnam., Le Minh NH; GSK, Ho Chi Minh City, Vietnam. minh.l.nguyen-hoan@gsk.com. |
| المصدر: | Infectious diseases and therapy [Infect Dis Ther] 2024 Mar; Vol. 13 (3), pp. 423-437. Date of Electronic Publication: 2024 Mar 02. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : [Auckland] Adis Original Publication: [London] : Springer Healthcare |
| مستخلص: | An advisory board meeting was held with experts in Vietnam (Hanoi, August 2022), to review the evidence on invasive meningococcal disease (IMD) epidemiology, clinical management, and meningococcal vaccines to reach a consensus on recommendations for meningococcal vaccination in Vietnam. IMD is a severe disease, with the highest burden in infants and children. IMD presents as meningitis and/or meningococcemia and can progress extremely rapidly. Almost 90% of deaths in children occur within the first 24 h, and disabling sequelae (e.g., limb amputations and neurological damage) occur in up to 20% of survivors. IMD patients are often hospitalized late, due to mild and nonspecific early symptoms and misdiagnosis. Difficulties related to diagnosis and antibiotic misuse mean that the number of reported IMD cases in Vietnam is likely to be underestimated. Serogroup B IMD is predominant in many regions of the world, including Vietnam, where 82% of IMD cases were due to serogroup B (surveillance data from 2012 to 2021). Four component meningococcal B vaccine (4CMenB) is used in many countries (and is part of the pediatric National Immunization Program in 13 countries), with infant vaccination starting from two months of age, and a 2 + 1 dosing schedule. Experts recommend 4CMenB vaccination as soon as possible in Vietnam, starting from two months of age, with a 2 + 1 dosing schedule, and at least completing one dose before 6 months of age. (© 2024. The Author(s).) |
| References: | The Nguyen PN, Hung NT, Mathur G, Pinto TJP, Minh NHL. Review of the epidemiology, diagnosis and management of invasive meningococcal disease in Vietnam. Hum Vaccin Immunother. 2023;19(1):2172922. https://doi.org/10.1080/21645515.2023.2172922 . (PMID: 10.1080/21645515.2023.21729223695116110072114) Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. https://doi.org/10.1186/1478-7954-11-17 . (PMID: 10.1186/1478-7954-11-17240163393848799) Centers for Disease Control and Prevention (CDC) Enhanced meningococcal disease surveillance report, 2020. 2023. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2020.pdf . Accessed 06 March 2023. Centers for Disease Control and Prevention (CDC) Enhanced meningococcal disease surveillance report, 2018. 2023. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf . Accessed 06 March 2023. European Centre for Disease Prevention and Control (ECDC) Invasive meningococcal disease. Annual epidemiological report for 2018. 2023. https://www.ecdc.europa.eu/en/publications-data/invasive-meningococcal-disease-annual-epidemiological-report-2018 . Accessed 06 March 2023. Alderson MR, Arkwright PD, Bai X, et al. Surveillance and control of meningococcal disease in the COVID-19 era: a global meningococcal initiative review. J Infect. 2022;84(3):289–96. https://doi.org/10.1016/j.jinf.2021.11.016 . (PMID: 10.1016/j.jinf.2021.11.01634838594) European Centre for Disease Prevention and Control (ECDC) Surveillance Atlas of Infectious Diseases. Invasive meningococcal disease 2018–2021. 2023. https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases . Accessed 08 March 2023. Ceyhan M, Ozsurekci Y, Basaranoglu ST, et al. Multicenter hospital-based prospective surveillance study of bacterial agents causing meningitis and seroprevalence of different serogroups of Neisseria meningitidis, Haemophilus influenzae Type b, and Streptococcus pneumoniae during 2015 to 2018 in Turkey. mSphere. 2020;5(2):e00060-20. https://doi.org/10.1128/mSphere.00060-20 . (PMID: 10.1128/mSphere.00060-20322136207096621) Aye AMM, Bai X, Borrow R, et al. Meningococcal disease surveillance in the Asia-Pacific region (2020): the global meningococcal initiative. J Infect. 2020;81(5):698–711. https://doi.org/10.1016/j.jinf.2020.07.025 . (PMID: 10.1016/j.jinf.2020.07.02532730999) Thisyakorn U, Carlos J, Chotpitayasunondh T, et al. Invasive meningococcal disease in Malaysia, Philippines, Thailand, and Vietnam: an Asia-Pacific expert group perspective on current epidemiology and vaccination policies. Hum Vaccin Immunother. 2022;18(6):2110759. https://doi.org/10.1080/21645515.2022.2110759 . (PMID: 10.1080/21645515.2022.2110759360843119746482) Kim SA, Kim DW, Dong BQ, Kim JS, Anh DD, Kilgore PE. An expanded age range for meningococcal meningitis: molecular diagnostic evidence from population-based surveillance in Asia. BMC Infect Dis. 2012;12:310. https://doi.org/10.1186/1471-2334-12-310 . (PMID: 10.1186/1471-2334-12-310231640613519641) Public Health Agency of Canada Vaccine preventable disease - Surveillance report to December 31, 2019. 2022. https://www.canada.ca/en/public-health/services/publications/healthy-living/vaccine-preventable-disease-surveillance-report-2019.html . Accessed 08 March 2023. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710–6. https://doi.org/10.1016/j.vaccine.2012.03.011 . (PMID: 10.1016/j.vaccine.2012.03.01122429756) Marshall HS. Meningococcal surveillance in Southeast Asia and the Pacific. Microbiol Aust. 2021;42(4):178–81. https://doi.org/10.1071/MA21050 . (PMID: 10.1071/MA21050) Pham TH, Vo TTD, Phan VT, Uong NDN, Nguyen TKH. Serogroup and antibiotic resistance of Neisseria meningitidis on recruits in some military barracks in the northern region men, 2012–2014. J Prev Med. 2014;55(11):160. Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 Suppl):S12-20. https://doi.org/10.1016/j.jadohealth.2016.03.041 . (PMID: 10.1016/j.jadohealth.2016.03.04127449145) Meningitis Research Foundation 90% of children and teenagers who die of meningococcal meningitis die within 24 hours. 2020. https://www.meningitis.org/research-into-how-fast-meningitis-kills . Accessed 10 March 2023. The Nguyen PN. A case report on fulminant meningicoccal infection in infant. Tien Giang Hospital Medicine Conference, Vietnam, 2021. Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M. Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect. 2011;139(7):967–85. https://doi.org/10.1017/S0950268811000574 . (PMID: 10.1017/S095026881100057421492496) Guiducci S, Moriondo M, Nieddu F, et al. Culture and real-time polymerase chain reaction sensitivity in the diagnosis of invasive meningococcal disease: does culture miss less severe cases? PLoS ONE. 2019;14(3): e0212922. https://doi.org/10.1371/journal.pone.0212922 . (PMID: 10.1371/journal.pone.0212922308656716415896) Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis. 2010;10(2):112–24. https://doi.org/10.1016/s1473-3099(09)70324-x . (PMID: 10.1016/s1473-3099(09)70324-x20113980) Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138(12):4402–7. (PMID: 10.4049/jimmunol.138.12.44023108388) Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000;287(5459):1809–15. https://doi.org/10.1126/science.287.5459.1809 . (PMID: 10.1126/science.287.5459.180910710307) European Medicines Agency (EMA) Bexsero European public assessment report, Annex I: summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002333/WC500137881.pdf . Accessed 10 March 2023. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501–10. https://doi.org/10.4049/jimmunol.177.1.501 . (PMID: 10.4049/jimmunol.177.1.50116785547) Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195(11):1445–54. https://doi.org/10.1084/jem.20020407 . (PMID: 10.1084/jem.20020407120452422193550) Martin DR, Ruijne N, McCallum L, O’Hallahan J, Oster P. The VR2 epitope on the PorA P1.7–2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13(4):486–91. https://doi.org/10.1128/cvi.13.4.486-491.2006 . (PMID: 10.1128/cvi.13.4.486-491.2006166036161459632) Martinón-Torres F, Carmona Martinez A, Simkó R, et al. Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: a randomised trial. J Infect. 2018;76(3):258–69. https://doi.org/10.1016/j.jinf.2017.12.005 . (PMID: 10.1016/j.jinf.2017.12.00529253560) Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–35. https://doi.org/10.1016/s0140-6736(12)61961-8 . (PMID: 10.1016/s0140-6736(12)61961-823324563) Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother. 2014;10(7):1993–2004. https://doi.org/10.4161/hv.28666 . (PMID: 10.4161/hv.28666254248094186040) Sohn W, Tahrat H, Abitbol V, Bekkat-Berkani R. Review of the four-component meningococcal serogroup b vaccine registrations, recommendations, and use in regional and national immunization programs. Geneva: European Society for Paediatric Infectious Diseases (ESPID); 2021. European Centre for Disease Prevention and Control (ECDC) Meningococcal Disease: Recommended vaccinations. 2023. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1 . Accessed 14 July 2023. Sohn W-Y, Tahrat H, Novy P, Bekkat-Berkani R. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices. Expert Rev Vaccines. 2022;21(3):325–35. https://doi.org/10.1080/14760584.2022.2021881 . (PMID: 10.1080/14760584.2022.202188135068299) Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–5. https://doi.org/10.1016/j.vaccine.2019.06.021 . (PMID: 10.1016/j.vaccine.2019.06.02131239214) Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. https://doi.org/10.1056/NEJMoa1901229 . (PMID: 10.1056/NEJMoa190122931971676) Rodrigues FMP, Marlow R, Simões MJ, Danon L, Ladhani S, Finn A. Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187–94. https://doi.org/10.1001/jama.2020.20449 . (PMID: 10.1001/jama.2020.20449332588897709085) Watson PS, Turner DP. Clinical experience with the meningococcal B vaccine, Bexsero(®): prospects for reducing the burden of meningococcal serogroup B disease. Vaccine. 2016;34(7):875–80. https://doi.org/10.1016/j.vaccine.2015.11.057 . (PMID: 10.1016/j.vaccine.2015.11.05726686570) Biswas HH, Han GS, Wendorf K, et al. Notes from the field: outbreak of serogroup b meningococcal disease at a University California, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(20):520–1. https://doi.org/10.15585/mmwr.mm6520a3 . (PMID: 10.15585/mmwr.mm6520a327227576) Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and Impact of the 4CMenB vaccine against group b meningococcal disease in two italian regions using different vaccination schedules: a five-year retrospective observational study (2014–2018). Vaccines (Basel). 2020. https://doi.org/10.3390/vaccines8030469 . (PMID: 10.3390/vaccines803046932842669) McMillan M, Wang B, Koehler AP, Sullivan TR, Marshall HS. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73(1):e233–7. https://doi.org/10.1093/cid/ciaa1636 . (PMID: 10.1093/cid/ciaa163633587122) Mentzer D, Oberle D, Keller-Stanislawski B. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Eurosurveillance. 2018;23(17):17–00468. https://doi.org/10.2807/1560-7917.ES.2018.23.17.17-00468 . (PMID: 10.2807/1560-7917.ES.2018.23.17.17-00468297176975930728) Agenzia Italiana del Farmaco (AIFA) Rapporto Vaccini. 2017. https://www.aifa.gov.it/sites/default/files/Rapp_Vaccini_2017_0.pdf . Accessed 10 March 2023. Australian Government Department of Health and Aged Care Bexsero meningococcal B vaccine. Final update monitoring finds no new or unexpected safety issues. 2016. https://www.tga.gov.au/news/safety-alerts/bexsero-meningococcal-b-vaccine . Accessed 10 March 2023. Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395–403. https://doi.org/10.1016/s2352-4642(18)30103-2 . (PMID: 10.1016/s2352-4642(18)30103-230169281) Andrews N, Stowe J, Miller E. Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: an ecological study. Vaccine. 2020;38(31):4816–9. https://doi.org/10.1016/j.vaccine.2020.05.055 . (PMID: 10.1016/j.vaccine.2020.05.05532482458) Stowe J, Andrews NJ, Turner PJ, Miller E. The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: a self-controlled case-series analysis. Vaccine. 2020;38(32):4935–9. https://doi.org/10.1016/j.vaccine.2020.05.089 . (PMID: 10.1016/j.vaccine.2020.05.08932536544) Hall GC, Douglas I, Heath PT, et al. Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program. Vaccine. 2021;39(24):3296–303. https://doi.org/10.1016/j.vaccine.2021.02.065 . (PMID: 10.1016/j.vaccine.2021.02.06533962840) De Serres G, Billard MN, Gariépy MC, et al. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine. 2018;36(52):8039–46. https://doi.org/10.1016/j.vaccine.2018.10.095 . (PMID: 10.1016/j.vaccine.2018.10.09530467063) Marshall HS, Koehler AP, Wang B, et al. Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia. Vaccine. 2020;38(37):5914–22. https://doi.org/10.1016/j.vaccine.2020.07.009 . (PMID: 10.1016/j.vaccine.2020.07.00932712083) Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–27. https://doi.org/10.1056/NEJMoa1900236 . (PMID: 10.1056/NEJMoa190023631971677) Thabuis A, Tararbit K, Taha MK, et al. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination. Eurosurveillance. 2018. https://doi.org/10.2807/1560-7917.Es.2018.23.28.1700590 . (PMID: 10.2807/1560-7917.Es.2018.23.28.1700590300170226152148) Ceyhan M, Gürler N, Ozsurekci Y, et al. Meningitis caused by Neisseria meningitidis, Hemophilus influenzae Type B and Streptococcus pneumoniae during 2005–2012 in Turkey. A multicenter prospective surveillance study. Hum Vaccin Immunother. 2014;10(9):2706–12. https://doi.org/10.4161/hv.29678 . (PMID: 10.4161/hv.29678254834874977434) Ceyhan M, Ozsurekci Y, Gürler N, et al. Bacterial agents causing meningitis during 2013–2014 in Turkey: a multi-center hospital-based prospective surveillance study. Hum Vaccin Immunother. 2016;12(11):2940–5. https://doi.org/10.1080/21645515.2016.1209278 . (PMID: 10.1080/21645515.2016.1209278274544685137527) |
| فهرسة مساهمة: | Keywords: 4CMenB; Infant; Invasive meningococcal disease; Vaccination; Vietnam |
| تواريخ الأحداث: | Date Created: 20240302 Latest Revision: 20240813 |
| رمز التحديث: | 20240813 |
| مُعرف محوري في PubMed: | PMC10965853 |
| DOI: | 10.1007/s40121-023-00905-y |
| PMID: | 38430327 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!